Bluebird Bio Stock Performance
| BLUE Stock | USD 0.38 0.01 2.70% |
The firm shows a Beta (market volatility) of 1.9, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bluebird Bio will likely underperform. At this point, Bluebird bio has a negative expected return of -0.5%. Please make sure to confirm Bluebird Bio's skewness, as well as the relationship between the rate of daily change and price action indicator , to decide if Bluebird bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bluebird bio has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1544:1000 | Last Split Date 2021-11-05 |
1 | New data underline cancer risk of Bluebird therapy for brain disease | 10/10/2024 |
2 | bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society ... | 11/05/2024 |
3 | Acquisition by Vachon Mark of 49850 shares of Bluebird Bio at 0.44 subject to Rule 16b-3 | 11/06/2024 |
4 | After Plunging -22.76 percent in 4 Weeks, Heres Why the Trend Might Reverse for Bluebird | 11/08/2024 |
5 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS LAUNCHES REFRESHED HEALTH EQUITY BUSINESS ACCELERATOR WITH MASSCHALLENGE | 11/12/2024 |
6 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS CONTINUES TO EXPAND ACCESS TO WOMENS HEALTH SERVICES AND FAMILY SUPPORT OPTIONS | 11/13/2024 |
7 | bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance | 11/14/2024 |
8 | JPMorgan skeptical of bluebird bio stock recovery, downgrades to underweight | 11/15/2024 |
9 | BLUE CROSS BLUE SHIELD OF MASSACHUSETTS ANNOUNCES NEW GRANTS AS PART OF ONGOING WORK TO ADDRESS HEALTH INEQUITIES | 11/20/2024 |
10 | FDA investigating safety risks of bluebirds Skysona | 11/27/2024 |
| Begin Period Cash Flow | 158.4 M |
Bluebird |
Bluebird Bio Relative Risk vs. Return Landscape
If you would invest 57.00 in Bluebird bio on August 31, 2024 and sell it today you would lose (19.00) from holding Bluebird bio or give up 33.33% of portfolio value over 90 days. Bluebird bio is currently does not generate positive expected returns and assumes 5.2424% risk (volatility on return distribution) over the 90 days horizon. In different words, 46% of stocks are less volatile than Bluebird, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bluebird Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bluebird Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bluebird bio, and traders can use it to determine the average amount a Bluebird Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0963
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLUE |
Estimated Market Risk
| 5.24 actual daily | 46 54% of assets are more volatile |
Expected Return
| -0.5 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Bluebird Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bluebird Bio by adding Bluebird Bio to a well-diversified portfolio.
Bluebird Bio Fundamentals Growth
Bluebird Stock prices reflect investors' perceptions of the future prospects and financial health of Bluebird Bio, and Bluebird Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bluebird Stock performance.
| Return On Equity | -1.87 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (5.49) % | ||||
| Current Valuation | 371.21 M | ||||
| Shares Outstanding | 194.44 M | ||||
| Price To Earning | (19.32) X | ||||
| Price To Book | 0.73 X | ||||
| Price To Sales | 1.34 X | ||||
| Revenue | 29.5 M | ||||
| Gross Profit | (247.24 M) | ||||
| EBITDA | (302.11 M) | ||||
| Net Income | (211.91 M) | ||||
| Cash And Equivalents | 132.51 M | ||||
| Cash Per Share | 1.72 X | ||||
| Total Debt | 424.62 M | ||||
| Debt To Equity | 1.63 % | ||||
| Current Ratio | 1.12 X | ||||
| Book Value Per Share | 1.01 X | ||||
| Cash Flow From Operations | (235.05 M) | ||||
| Earnings Per Share | (1.80) X | ||||
| Market Capitalization | 73.46 M | ||||
| Total Asset | 619.16 M | ||||
| Retained Earnings | (4.26 B) | ||||
| Working Capital | 81.57 M | ||||
| Current Asset | 523.97 M | ||||
| Current Liabilities | 40.37 M | ||||
About Bluebird Bio Performance
By analyzing Bluebird Bio's fundamental ratios, stakeholders can gain valuable insights into Bluebird Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bluebird Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bluebird Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 249.51 | 261.99 | |
| Return On Tangible Assets | (0.35) | (0.37) | |
| Return On Capital Employed | (0.58) | (0.61) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.09) | (1.03) |
Things to note about Bluebird bio performance evaluation
Checking the ongoing alerts about Bluebird Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bluebird bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bluebird bio generated a negative expected return over the last 90 days | |
| Bluebird bio has high historical volatility and very poor performance | |
| Bluebird bio has some characteristics of a very speculative penny stock | |
| Bluebird bio has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 29.5 M. Net Loss for the year was (211.91 M) with loss before overhead, payroll, taxes, and interest of (247.24 M). | |
| Bluebird bio currently holds about 132.51 M in cash with (235.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Bluebird bio has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from seekingalpha.com: FDA investigating safety risks of bluebirds Skysona |
- Analyzing Bluebird Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bluebird Bio's stock is overvalued or undervalued compared to its peers.
- Examining Bluebird Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bluebird Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bluebird Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bluebird Bio's stock. These opinions can provide insight into Bluebird Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bluebird Stock analysis
When running Bluebird Bio's price analysis, check to measure Bluebird Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluebird Bio is operating at the current time. Most of Bluebird Bio's value examination focuses on studying past and present price action to predict the probability of Bluebird Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluebird Bio's price. Additionally, you may evaluate how the addition of Bluebird Bio to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |